5/1/2014 2:51:27 PM
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended March 31, 2014.
“We are pleased with the quarter’s results. Patients benefitted from several significant generic and specialty medicine launches, most notably our Copaxone® 40mg in the U.S. Our global generics business delivered increased profitability, and our U.S. generics revenues were up 17% year-over-year,” stated Erez Vigodman, President and CEO of Teva.
Help employers find you! Check out all the jobs and post your resume.
comments powered by